Axial Therapeutics

Headquarters: Cambridge, Massachusetts, USA
Founded: 2016
Focus: Gut-brain axis therapeutics for neurodegenerative diseases
Stage: Clinical-stage biopharmaceutical company
Website: axialtx.com

Overview

flowchart TD
    therapeutics["therapeutics"] -->|"protects against"| age_related_cognitive_decline["age-related cognitive decline"]
    therapeutics["therapeutics"] -->|"inhibits"| neuroinflammation["neuroinflammation"]
    Therapeutics["Therapeutics"] -->|"references"| SIRT6["SIRT6"]
    Therapeutics["Therapeutics"] -->|"references"| AADC["AADC"]
    Therapeutics["Therapeutics"] -->|"references"| CX3CR1["CX3CR1"]
    Therapeutics["Therapeutics"] -->|"references"| BACE1["BACE1"]
    Therapeutics["Therapeutics"] -->|"references"| APOE["APOE"]
    Therapeutics["Therapeutics"] -->|"references"| VCP["VCP"]
    Therapeutics["Therapeutics"] -->|"references"| GFAP["GFAP"]
    Therapeutics["Therapeutics"] -->|"references"| NURR1["NURR1"]
    Therapeutics["Therapeutics"] -->|"references"| BDNF["BDNF"]
    Therapeutics["Therapeutics"] -->|"references"| NLRP3["NLRP3"]
    Therapeutics["Therapeutics"] -->|"references"| TFEB["TFEB"]
    Therapeutics["Therapeutics"] -->|"references"| PPARGC1A["PPARGC1A"]
    style therapeutics fill:#4fc3f7,stroke:#333,color:#000

Axial Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases by targeting the gut-brain axis. The company’s approach focuses on modulating the microbiome to reduce neuroinflammation and protect neuronal function.

Founded in 2016 and headquartered in Cambridge, Massachusetts, Axial Therapeutics represents a pioneering approach in neurodegenerative disease drug development. The company recognizes that the gut-brain connection represents an untapped therapeutic target that could address the underlying causes of diseases like Parkinson’s disease and Alzheimer’s disease, rather than just managing symptoms.

Company Background

Axial Therapeutics was founded by a team of neuroscientists, microbiologists, and drug development experts who recognized the emerging evidence connecting gut health to neurodegenerative disease progression. The company’s scientific co-founders brought expertise in microbiome research, neuroinflammation, and translational medicine.

The company’s name reflects its core therapeutic approach—“axial” refers to the axis between the gut and the brain, the central pathway through which their drug candidates exert their effects. This innovative positioning has attracted significant investor interest and strategic partnerships with major pharmaceutical companies.

Cambridge, Massachusetts, provides Axial with access to a rich ecosystem of biotechnology companies, world-class research institutions, and experienced drug development talent. The proximity to MIT, Harvard, and leading hospital systems has facilitated academic collaborations and access to cutting-edge research.

Funding and Investment

Axial Therapeutics has raised capital through multiple financing rounds:

• Series A: Initial venture funding to establish research programs

• Series B: Expanded funding to advance clinical development

• Strategic Partnership: Collaboration funding from AbbVie

The company has also benefited from non-dilutive funding through NIH grants supporting microbiome research and neurodegenerative disease studies.

Pipeline and Programs

ABBV-5523 (formerly AX-5904)

Axial’s lead program is ABBV-5523, a small molecule inhibitor designed to modulate gut microbiome-derived metabolites that contribute to neurodegeneration. The compound targets pathogenic bacterial metabolites that promote neuroinflammation and alpha-synuclein aggregation in Parkinson’s disease^{1Axial Therapeutics Partners with AbbVie to Develop [Microbiome](/mechanisms/microbiome-neurodegeneration)-Based Therapeutics for Neurodegenerative DiseasesOpen reference}.

• Indication: Parkinson’s disease

• Mechanism: Small molecule inhibitor of gut-brain axis signaling

• Development Stage: Clinical development

• Partner: AbbVie (collaboration announced 2022)

ABBV-5523 represents a novel approach in the Parkinson’s disease therapeutic landscape. Unlike traditional dopamine-replacement therapies that address symptoms but do not modify disease progression, ABBV-5523 targets what Axial believes to be a root cause of disease progression—the influence of gut-derived inflammatory molecules on brain function.

The drug candidate works by:

1. Blocking the absorption of pathogenic bacterial metabolites

2. Reducing systemic inflammation that reaches the brain

3. Preventing microbiome-induced alpha-synuclein misfolding

4. Protecting dopaminergic neurons from inflammatory damage

ABBV-5524

A second program in development for Alzheimer’s disease, targeting similar microbiome-mediated inflammatory pathways^{1Axial Therapeutics Partners with AbbVie to Develop [Microbiome](/mechanisms/microbiome-neurodegeneration)-Based Therapeutics for Neurodegenerative DiseasesOpen reference}.

• Indication: Alzheimer’s disease

• Mechanism: Microbiome modulation to reduce neuroinflammation

• Development Stage: Preclinical/IND-enabling

Additional Pipeline Programs

Axial maintains a discovery pipeline exploring:

• Additional small molecules targeting gut-brain signaling

• Biomarker programs to identify patients most likely to benefit

• Combination therapy approaches with existing Parkinson’s medications

Scientific Approach

The Gut-Brain Axis in Neurodegeneration

The gut-brain axis represents an emerging frontier in neurodegenerative disease research. Axial Therapeutics targets the connection between intestinal microbiota and central nervous system function through several mechanisms^{2The [Gut-Brain Axis](/mechanisms/gut-brain-axis-neurodegeneration) in NeurodegenerationOpen reference}:

1. Microbiome modulation: Reducing levels of pro-inflammatory bacterial metabolites

2. Neuroprotection: Protecting neurons from inflammation-induced damage

3. Alpha-synuclein aggregation prevention: Blocking bacterial metabolites that promote protein misfolding

4. Gut barrier integrity: Improving gut epithelial barrier function to reduce systemic inflammation

Pathogenic Mechanism

Research has demonstrated that individuals with Parkinson’s disease harbor distinct gut microbiome compositions compared to healthy controls. These differences include:

• Reduced microbial diversity

• Increased levels of pro-inflammatory bacteria

• Elevated production of metabolic byproducts that can cross the gut barrier

• Compromised intestinal permeability (“leaky gut”)

The gut dysfunction often precedes motor symptoms in Parkinson’s disease by years, suggesting that microbiome changes may contribute to disease initiation or early progression^{3Gut Microbiota in Parkinson's DiseasePMID 34549876Open reference}. This observation provides a window for early intervention that Axial’s therapeutics aim to exploit.

Therapeutic Rationale

By targeting the gut-brain axis, Axial’s approach offers several potential advantages:

• Disease modification: Addressing upstream drivers of neurodegeneration

• Early intervention: Potential for treatment before significant neuronal loss

• Combination potential: Compatible with symptomatic treatments

• Peripheral targeting: Avoiding challenges of direct CNS drug delivery

Clinical Development Strategy

Axial’s clinical development program focuses on:

1. Patient selection: Identifying biomarkers that predict treatment response

2. Disease staging: Targeting patients at stages where intervention may be most beneficial

3. Combination studies: Exploring integration with standard-of-care Parkinson’s treatments

4. Long-term outcomes: Measuring disease progression markers rather than just symptoms

Partnerships and Collaborations

AbbVie Collaboration (2022)

In 2022, Axial Therapeutics announced a strategic collaboration with AbbVie to develop and commercialize microbiome-based therapeutics for neurodegenerative diseases. This partnership provides:

• Significant development funding

• AbbVie’s global commercial infrastructure

• Combined expertise in clinical development

• Resources to advance multiple programs simultaneously

Academic Collaborations

Axial maintains active research collaborations with leading institutions studying the gut-brain axis:

• Universities with prominent neuroscience programs

• Research hospitals with Parkinson’s disease centers

• Microbiome research institutes

Recent Developments

The field of gut-brain axis therapeutics continues to evolve rapidly. Key developments for Axial include:

• Advancement of ABBV-5523 into clinical trials

• Publication of preclinical data supporting mechanism of action

• Expansion of biomarker research programs

• Growing validation of microbiome approaches in neurodegeneration

See Also

• [Parkinson’s Disease)

• Alzheimer’s Disease](/diseases/alzheimers-disease)

• Gut-Brain Axis

• Microbiome

• Alpha-Synuclein

• Neuroinflammation

• Neurodegenerative Disease Therapeutics

External Links

• Axial Therapeutics Official Site

• Axial Therapeutics - LinkedIn